RHB-204 Orphan Drug designation and QIDP designation extend potential market exclusivity up to 12 years post-approval and provide eligibility for Fast-Track development and NDA Priority Review TEL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results